Enzyme-triggered PEGylated pDNA-nanoparticles for controlled release of pDNA in tumors.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Bioconjugate chemistry

• Publication date

  2013-02-19

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/bc300419gPMID 23305338
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In vivo delivery of RNAi with lipid-based nanoparticles.

  2011cited by this paper
• Efficient topical delivery of plasmid DNA to lung in vivo mediated by putative triggered, PEGylated pDNA nanoparticles.

  2011cited by this paper
• Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits

  2010cited by this paper
• Caveolin-1 regulating the invasion and expression of matrix metalloproteinase (MMPs) in pancreatic carcinoma cells.

  2010cited by this paper
• Bioresponsive small molecule polyamines as noncytotoxic alternative to polyethylenimine.

  2010cited by this paper
• DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA.

  2010cited by this paper
• VAMP3, syntaxin-13 and SNAP23 are involved in secretion of matrix metalloproteinases, degradation of the extracellular matrix and cell invasion

  2009cited by this paper
• Folate receptor targeted bimodal liposomes for tumor magnetic resonance imaging.

  2009cited by this paper
• Novel peptide ligand directs liposomes toward EGF‐R high‐expressing cancer cells in vitro and in vivo

  2009cited by this paper
• Endostar Suppresses Invasion Through Downregulating the Expression of Matrix Metalloproteinase-2/9 in MDA-MB-435 Human Breast Cancer Cells

  2008cited by this paper
• Synthetic Nucleic Acid Delivery Systems in Gene Therapy

  2008cited by this paper
• Bimodal paramagnetic and fluorescent liposomes for cellular and tumor magnetic resonance imaging.

  2008cited by this paper
• Biophysical Properties of CDAN/DOPE‐Analogue Lipoplexes Account for Enhanced Gene Delivery

  2008cited by this paper
• Towards Safe Nanoparticle Technologies for Nucleic Acid Therapeutics

  2008cited by this paper
• MMPs-specific PEGylated peptide-DOX conjugate micelles that can contain free doxorubicin.

  2007cited by this paper
• Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid

  2007cited by this paper
• [Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid].

  2007cited by this paper
• A dialkynoyl analogue of DOPE improves gene transfer of lower-charged, cationic lipoplexes.

  2006cited by this paper
• Proteolytic actuation of nanoparticle self-assembly.

  2006cited by this paper
• In vivo studies of dialkynoyl analogues of DOTAP demonstrate improved gene transfer efficiency of cationic liposomes in mouse lung.

  2006cited by this paper
• Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting.

  2006cited by this paper
• Toxicity of cationic lipids and cationic polymers in gene delivery.

  2006cited by this paper
• Cationic lipids, lipoplexes and intracellular delivery of genes.

  2006cited by this paper
• Synthetic, self-assembly ABCD nanoparticles; a structural paradigm for viable synthetic non-viral vectors.

  2005cited by this paper
• Relaxivity of liposomal paramagnetic MRI contrast agents

  2005cited by this paper
• Matrilysin (MMP‐7) promotes invasion of ovarian cancer cells by activation of progelatinase

  2005cited by this paper
• Synthesis and Application of Integrin Targeting Lipopeptides in Targeted Gene Delivery

  2005cited by this paper
• TGFβ1 stimulates the secretion of matrix metalloproteinase 2 (MMP2) and the invasive behavior in human ovarian cancer cells, which is suppressed by MMP inhibitor BB3103

  2004cited by this paper
• Nanoparticle-Aptamer Bioconjugates

  2004cited by this paper
• The problem with cationic liposome/micelle-based non-viral vector systems for gene therapy.

  2003cited by this paper
• Characterisation of LMD virus-like nanoparticles self-assembled from cationic liposomes, adenovirus core peptide μ (mu) and plasmid DNA

  2002cited by this paper
• Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2

  2002cited by this paper
• Physico-chemical analysis of cationic liposome–DNA complexes (lipoplexes) with respect to in vitro and in vivo gene delivery efficiency

  2001cited by this paper
• TGFbeta1 stimulates the secretion of matrix metalloproteinase 2 (MMP2) and the invasive behavior in human ovarian cancer cells, which is suppressed by MMP inhibitor BB3103.

  2000cited by this paper
• Elastase activated liposomal delivery to nucleated cells.

  1999cited by this paper
• Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells.

  1998cited by this paper
• An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery.

  1998cited by this paper
• Polyamine Analogues of 3β-[N-(N′,N′-Dimethylaminoethane)carbamoyl]cholesterol (DC-Chol) as Agents for Gene Delivery

  1998cited by this paper
• Characterization of cationic lipid-protamine–DNA (LPD) complexes for intravenous gene delivery

  1998cited by this paper
• Inclusion of cholesterol in DOTAP transfection complexes increases the delivery of DNA to cells in vitro in the presence of serum

  1998cited by this paper
• Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes.

  1998cited by this paper
• Triggerable liposomal fusion by enzyme cleavage of a novel peptide-lipid conjugate.

  1998cited by this paper
• Physical properties and pharmacological activity in vitro and in vivo of optimised liposomes prepared from a new cancerostatic alkylphospholipid.

  1998cited by this paper
• Stabilization of cationic liposome‐plasmid DNA complexes by polyamines and poly(ethylene glycol)‐phospholipid conjugates for efficient in vivo gene delivery

  1997cited by this paper
• Improved DNA: liposome complexes for increased systemic delivery and gene expression

  1997cited by this paper
• Influence of cholesterol on the association of plasma proteins with liposomes.

  1996cited by this paper
• Autocrine factor enhancing the secretion of M(r) 95,000 gelatinase (matrix metalloproteinase 9) in serum-free medium conditioned with murine metastatic colon carcinoma cells.

  1994cited by this paper
• Characterization of interaction between DNA and 4',6-diamidino-2-phenylindole by optical spectroscopy.

  1987cited by this paper
• Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro.

  1980cited by this paper

• Recent advances in nanocarrier-based vaccines for enhanced immunotherapy

  2025cites this paper
• Innovative Theranostics Strategies in the Fight Against Lung Cancer.

  2025cites this paper
• A review of DNA nanoparticles-encapsulated drug/gene/protein for advanced controlled drug release: Current status and future perspective over emerging therapy approaches.

  2024cites this paper
• Structural and componential design: new strategies regulating the behavior of lipid-based nanoparticles in vivo.

  2023cites this paper
• Characterization of controlled-release Eucalyptus citriodora oil/Zinc ions nanoparticles with enhanced antibacterial properties against E. coli O157:H7 in fruit juice.

  2022cites this paper
• Nanoparticles for vaccine and gene therapy: Overcoming the barriers to nucleic acid delivery

  2022cites this paper
• Systematic Combination of Oligonucleotides and Synthetic Polymers for Advanced Therapeutic Applications

  2021cites this paper
• Stimulus-responsive liposomes for biomedical applications.

  2021cites this paper
• Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics

  2020cites this paper
• DePEGylation strategies to increase cancer nanomedicine efficacy.

  2019cites this paper
• Hydrazone-modulated peptides for efficient gene transfection.

  2017cites this paper
• Stimuli-responsive liposomes for drug delivery.

  2017cites this paper
• Stimuli-Regulated Smart Polymeric Systems for Gene Therapy

  2017cites this paper
• Molecular Communication Model for Targeted Drug Delivery in Multiple Disease Sites With Diversely Expressed Enzymes

  2016cites this paper
• Liposomes as Drug Delivery Vehicles

  2016cites this paper
• Nanomedicine therapeutics and diagnostics are the goal.

  2016cites this paper
• Chemical Structures of Lipids and Drug Used To Prepare Labeled Thermosensitive Liposomes Molecular Pharmaceutics

  2015cites this paper
• Interaction between cells and poly(ethylene glycol)-lipid conjugates.

  2015cites this paper
• Thermosensitive, near-infrared-labeled nanoparticles for topotecan delivery to tumors.

  2015cites this paper
• Multifunctional inorganic nanocontainers for DNA and drug delivery into living cells.

  2014cites this paper
• Enzyme-triggered PEGylated siRNA-nanoparticles for controlled release of siRNA

  2014cites this paper
• Cationic lipophosphoramidates with two different lipid chains: synthesis and evaluation as gene carriers.

  2014cites this paper
• Nanomedicine in Cancer Diagnosis and Therapy: Converging Medical Technologies Impacting Healthcare

  2014cites this paper
• Delivering the promise of small ncRNA therapeutics.

  2014cites this paper
• Bioresponsive polymer-based nucleic acid carriers.

  2014cites this paper
• MMP-9 Responsive PEG Cleavable Nanovesicles for Efficient Delivery of Chemotherapeutics to Pancreatic Cancer

  2014cites this paper
• Lipid-Based Nanoparticles in Cancer Diagnosis and Therapy

  2013cites this paper
• Bioresponsive HES-PEI conjugates for controlled shielding and deshielding of pDNA polyplexes

  2013cites this paper
• Delivery of RNAi therapeutics: work in progress

  2013cites this paper